Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019
Shots:
- The P-III study results involves assessing of Taltz in patients with moderate to severe plaque psoriasis for 5yrs.in addition to an extension study UNCOVER-1
- Collective results: 90%+ maintained skin clearance as measured by PASI 75; @264wks. PASI 75 (94.3); PASI 90 (81.8%); PASI 100 (46.6%)- presented at WCD with additional data of UNCOVER-3 study
- Taltz (80mg/ml- pre-filled syringe) is a mAb act by targeting IL-17A- being studied in 13 clinical studies in 17-000+ patients under Taltz clinical study program and is an approved therapy for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com